This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Second Look: Gaining Insight into the 52-Week Data Readout of Nektar Therapeutics’ Rezpegaldesleukin in Atopic Dermatitis

Ticker(s): NKTR

Who's the expert?

Institution: Aimee Payne Lab, Columbia University Irving Medical Center and Philipps University of Marburg and Charité

  • Associate Research Scientist & Dermatologist with a research focus on inflammatory and autoimmune skin diseases and T-cell immunology

  • Manages 300-400 patients per month with atopic dermatitis.

  • Work centered on immune-mediated mechanisms of skin disease, particularly T-cell immunology and antigen-specific immune responses, and he actively collaborates within the Payne lab to advance antigen-specific immunotherapies and translational research on autoimmune skin disorders. 

Interview Goal
To gain a deeper understanding of Nektar Therapeutics’ Rezpegaldesleukin as a potential treatment in atopic dermatitis

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.